Week in Review: CanSino Publishes Positive Data from Trial of COVID-19 Vaccine

Coronavirus Pandemic • Tianjin CanSinoBIO published positive results from a China Phase I trial of its Ad5 vectored COVID-19 vaccine in The Lancet; • Moderna, a Boston-area mRNA company, reported positive early data from four patients in a Phase I trial of its coronavirus vaccine; • Sinovac of Beijing raised $15 million to conduct Phase II trials of its COVID-19 vaccine; • CanSinoBIO and Canada's Precision NanoSystems partnered to develop a mRNA lipid nanoparticle vaccine for COVID-19; Deals and Financings • Peijia Medical of Suzhou completed a $302 million Hong Kong IPO for its minimally invasive medical devices; • Zentalis Pharma of the US formed a China subsidiary with $20 million of capital to develop three Zentalis oncology candidates in China; • Qingdao Primedicine in-licensed China rights to a novel drug that lowers damage following a heart attack from Primary Peptides of Canada; • Innovent, a Suzhou biotech, will collaborate with MD Anderson Cancer Center to test its PD-1 checkpoint inhibitor in patients with very rare cancers; Trials and Approvals • Apollomics, a US-China biopharma, will start a global Phase II trial of its c-MET inhibitor in NSCLC and GBM with c-MET abnormalities; • I-Mab of Shanghai announced approval to start a China Phase II trial of a novel long-acting interleukin-7 (rhIL-7) in patients with GBM; • Zai Lab of Shanghai dosed the first China patient in a global Phase III trial of a novel anti-infective; • Shanghai's CARsgen Therapeutics was approved to start US trials of a CAR-T therapy for several solid tumor cancers. Stock Symbols: (HK: 6185) (NSDQ: MRNA) (NSDQ: SVA) (HK: 09996) (NSDQ: ZNTL) (HK: 01801) (NSDQ: IMAB) (NSDQ: ZLAB) Share this with colleagues: // //